CDKN2A and ovarian cancer: P16 overexpression has been reported in 22 of 24 (90%) high-stage malignant ovarian tumours (Shigemasa et al, 1997), whereas other reports suggest a correlation between p16 underexpression and low-grade ovarian tumours; 22 out of 60 (37%) (Fujita et al, 1997).